Masa Juan F, Corral Jaime, Sanchez de Cos Julio, Duran-Cantolla Joaquin, Cabello Marta, Hernández-Blasco Luis, Monasterio Carmen, Alonso Alberto, Chiner Eusebi, Aizpuru Felipe, Vázquez-Polo Francisco-José, Zamorano Jose, Montserrat Jose M, Garcia-Ledesma Estefania, Pereira Ricardo, Cancelo Laura, Martinez Angeles, Sacristan Lirios, Salord Neus, Carrera Miguel, Sancho-Chust José N, Negrín Miguel A, Embid Cristina
San Pedro de Alcantara Hospital, Caceres, Spain ; CIBER de enfermedades respiratorias (CIBERES), Madrid, Spain.
Sleep. 2013 Dec 1;36(12):1799-807. doi: 10.5665/sleep.3204.
Home respiratory polygraphy (HRP) may be a cost-effective alternative to polysomnography (PSG) for diagnosis and treatment election in patients with high clinical probability of obstructive sleep apnea (OSA), but there is conflicting evidence on its use for a wider spectrum of patients.
To determine the efficacy and cost of OSA management (diagnosis and therapeutic decision making) using (1) PSG for all patients (PSG arm); (2) HRP for all patients (HRP arm); and (3) HRP for a subsample of patients with high clinical probability of being treated with continuous positive airway pressure (CPAP) and PSG for the remainder (elective HRP arm).
Multicentric study of 366 patients with intermediate-high clinical probability of OSA, randomly subjected to HRP and PSG. We explored the diagnostic and therapeutic decision agreements between the PSG and both HRP arms for several HRP cutoff points and calculated costs for equal diagnostic and/or therapeutic decision efficacy.
For equal diagnostic and therapeutic decision efficacy, PSG arm costs were 18% higher than HRP arm costs and 20% higher than elective HRP arm costs. HRP arm costs tended to be lower than elective HRP arm costs, and both tended to be lower than PSG arm costs if patient costs were omitted.
Home respiratory polygraphy is a less costly alternative than polysomnography for the diagnosis and therapeutic decision making for patients with suspected obstructive sleep apnea. We found no advantage in cost terms, however, in using home respiratory polygraphy for all patients or home respiratory polygraphy for the most symptomatic patients and polysomnography for the rest.
对于阻塞性睡眠呼吸暂停(OSA)临床可能性高的患者,家庭呼吸多导睡眠图(HRP)可能是一种比多导睡眠图(PSG)更具成本效益的诊断和治疗选择方法,但关于其在更广泛患者群体中的应用存在相互矛盾的证据。
确定使用以下方法进行OSA管理(诊断和治疗决策)的疗效和成本:(1)对所有患者使用PSG(PSG组);(2)对所有患者使用HRP(HRP组);(3)对临床高度可能接受持续气道正压通气(CPAP)治疗的患者子样本使用HRP,其余患者使用PSG(选择性HRP组)。
对366例具有中高OSA临床可能性的患者进行多中心研究,随机接受HRP和PSG检查。我们探讨了PSG与两个HRP组在几个HRP临界值时的诊断和治疗决策一致性,并计算了具有相同诊断和/或治疗决策疗效的成本。
在具有相同诊断和治疗决策疗效的情况下,PSG组的成本比HRP组高18%,比选择性HRP组高20%。如果不计算患者成本,HRP组的成本往往低于选择性HRP组,且两者都往往低于PSG组。
对于疑似阻塞性睡眠呼吸暂停的患者,家庭呼吸多导睡眠图在诊断和治疗决策方面是一种成本较低的替代方法。然而,我们发现在成本方面,对所有患者使用家庭呼吸多导睡眠图或对症状最明显的患者使用家庭呼吸多导睡眠图而其余患者使用多导睡眠图并无优势。